<DOC>
	<DOCNO>NCT00857857</DOCNO>
	<brief_summary>The study measure early late asthamtic response use allergen challenge . This study evaluate safety patient tolerance repeat inhaled dos GW870086X use number clinical biological marker .</brief_summary>
	<brief_title>A Study Evaluate Effect GW870086X Allergen Challenge Mild Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male subject 18 65 year age inclusive . Male subject must agree use one contraception method list Section 8 . This criterion must follow time first dose study medication 9095 hour postlast dose . BMI within range 19.0 29.0 kg/m2 ( inclusive ) . Liver function test ( bilirubin , AST , ALT ) within normal laboratory parameter screen . Documented history bronchial asthma , first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta agonist therapy inhalation . Prebronchodilator FEV1 &gt; 65 % predict screening . No history smoking within 6 month start study , total pack year history &lt; = 10 pack year Demonstration positive wheal flare reaction ( &gt; = 3 mm relative negative control ) least one allergen battery allergen ( include limit house dust mite , grass pollen , cat dander , hazel , horse birch ) skin prick test screening , within 12 month study start . Screening allergen challenge demonstrate subject experience early late asthmatic response . The early asthmatic response must include fall FEV1 &gt; = 20 % post saline value , least one occasion , 5 30 minute final concentration allergen . The late asthmatic response must include fall FEV1 &gt; = 15 % post saline value , least three occasion , two must consecutive , 4 10 hour final concentration allergen . Reproducible allergen challenge screening ( confirmation dose ascend allergen challenge bolus allergen challenge least 14 day later ) . Sensitivity methacholine provocative concentration methacholine result 20 % fall FEV1 ( PC20 methacholine ) &lt; 8 mg/mL screening . Subjects able produce acceptable induced sputum sample ( define Study Procedures Manual ) . Be able give write informed consent , include compliance requirement restriction list consent form . Single QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease ( include confine chronic bronchitis , emphysema , bronchiectasis pulmonary fibrosis ) . Clinically significant abnormality safety laboratory analysis screening . Subject known history hypertension hypertensive screening . Hypertension screen define persistent systolic BP &gt; 140mmHg diastolic BP &gt; 90mmHg . Respiratory tract infection and/or exacerbation asthma within 4 week prior first dose study medication . History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest and/or hypoxic seizure . Administration oral , injectable dermal steroid within 4 week intranasal and/or inhaled steroid within 2 week screen visit . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit average daily intake great 3 unit ( male ) . One unit equivalent halfpint ( 220mL ) beer 1 ( 25ml ) measure spirit 1 glass ( 125ml ) wine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Paracetamol exception permit daily dos 4 g screen followup . Has take Xanthines ( include theophylline , include caffeine ) , anticholinergic , cromoglycates and/or longacting betaagonists within 1 week prior screen unable abstain throughout study . Unable abstain medication include nonsteroidal antiinflammatory drug ( NSAIDs ) , antidepressant drug , antihistamine antiasthma ( include steroid ) , antirhinitis hay fever medication , short act inhaled betaagonists paracetamol ( 4 g per day ) treatment minor ailment eg headache 7 day screen followup visit . Unable abstain medication supplement significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 , include ritonavir ketoconazol screen throughout study . Unable use DISKHALER and/or DISKUS device correctly . History unable tolerate complete methacholine allergen challenge test . If , 2 concurrent administration saline allergen challenge screen subject still fall FEV1 great 10 % . Subject undergoing allergen desensitisation therapy . History sensitivity study medication ( include lactose ) , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . Subjects kept due regulatory juridical order institution . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 3 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>late phase response</keyword>
	<keyword>allergen</keyword>
	<keyword>challenge</keyword>
	<keyword>GW870086X</keyword>
</DOC>